SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : GZTC

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: LTK007 who wrote (591)11/15/1998 2:26:00 PM
From: Street Walker   of 752
 
Technical Analysis

investools.com
Input March 98- present day.
increase size of chart one notch
put in moving averages, and then click for chart

GZTC has moved beyond its 10 dma, 25 dma, 50 dma, 70 dma,
is hovering above its 100 dma, and next resistance
is the 200 dma at around 7 3/8. When it passes that, it will
be a break-out.

All the moving averages are tending upward.

Yes, the patent gives LONGTERM VALUE
>>>>>>The patent grants Genzyme Transgenics exclusive rights to the transgenic production of immunoglobulins in
commercially useful levels in the milk of mammals.

''This patent gives Genzyme Transgenics a broad proprietary position in transgenic production of monoclonal and other types
of assembled antibodies,''

Currently, several hundred monoclonal antibodies are in preclinical and clinical development for disorders including heart
disease, cancer, rheumatoid arthritis, and infectious diseases, including AIDS. <<<<<<<<<<<<<<
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext